FDA grants EUA for Pfizer-BioNTech’s Covid-19 booster in children
The expanded EUA for use of booster dose in children is based on the findings from a Phase II/III clinical…
News
Latest in
News
AbbVie to licence Cugene’s therapies for autoimmune diseases
Under the deal, AbbVie will make an upfront payment of $48.5m to Cugene.
Kriya Therapeutics raises $270m in Series C funding round
The company intends to use the funds to advance its pipeline and scaling of its platforms.
FDA declines to grant EUA for antidepressant to treat Covid-19
The data was inadequate to conclude that the drug was effective in preventing disease progression, FDA noted.
Lilly’s Mounjaro receives FDA approval for type 2 diabetes treatment
The approval is based on findings from the Phase III SURPASS programme of Mounjaro.
EC to terminate Covid-19 vaccine deal with Valneva
The EC can terminate the agreement if the vaccine does not obtain marketing authorisation from EMA by the end of…
Pfizer and BioNTech amend Covid-19 vaccine supply deal with EC
The vaccine doses planned to be supplied between June and August will now be delivered from September to Q4 of…
FDA grants Orphan Drug Designation to Editas’ beta thalassemia therapy
The company intends to commence a Phase I/II trial of EDIT-301 in transfusion-dependent beta thalassemia patients this year.